Remove 2023 Remove Documentation Remove Medication Dispensing
article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

Medications dispensed through these clinics have high utilization rates, and yield equally high 340B savings. We handle the rest of the process — painstakingly documenting everything we do, and reporting back to the health systems at every critical step. Fortunately, those steps tend to be the least burdensome in the process.

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

Medications dispensed through these clinics have high utilization rates, and yield equally high 340B savings. We handle the rest of the process — painstakingly documenting everything we do, and reporting back to the health systems at every critical step. Fortunately, those steps tend to be the least burdensome in the process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

Medications dispensed through these clinics have high utilization rates, and yield equally high 340B savings. We handle the rest of the process — painstakingly documenting everything we do, and reporting back to the health systems at every critical step. Fortunately, those steps tend to be the least burdensome in the process.

article thumbnail

New Breakthrough Devices Program Guidance: Expanding Opportunities for Medical Product Innovations

FDA Law Blog: Biosimilars

Background The Breakthrough Devices Program, established under section 515B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), is a voluntary program for certain medical devices and device-led combination products. By Philip Won & Lisa M. Wysa, see here ) and addiction (e.g., reSET-O, see here , here ).